Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
August 10, 2022 06:30 ET
|
Centessa Pharmaceuticals plc
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for...
Centessa Pharmaceuticals Announces Addition of Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs
July 25, 2022 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation...
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
July 01, 2022 08:40 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
June 06, 2022 08:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation...
Centessa Pharmaceuticals Announces Poster Presentation of First Preclinical Data for LockBody® Program at 2022 ASCO Annual Meeting
June 05, 2022 07:00 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation...
Centessa Pharmaceuticals Makes Strategic Decision to Discontinue Clinical Development of Lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
June 02, 2022 06:29 ET
|
Centessa Pharmaceuticals plc
- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study - - Discontinuation of lixivaptan development expected to...
Centessa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Updates
May 16, 2022 07:00 ET
|
Centessa Pharmaceuticals plc
– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022 to highlight LB101...
Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
March 30, 2022 16:01 ET
|
Centessa Pharmaceuticals plc
– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022...
Centessa Pharmaceuticals to Present at the Guggenheim Genomic Medicines & Rare Disease Day
March 23, 2022 16:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim...
Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
March 07, 2022 07:30 ET
|
Centessa Pharmaceuticals plc
BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the “Company”), a clinical-stage company leveraging its innovative asset-centric business model to...